Homologous Recombination Deficiency clinical trials at UCLA
1 research study open to eligible people
open to eligible people ages 18 years and up
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Los Angeles, California and other locations
Our lead scientists for Homologous Recombination Deficiency research studies include Lee Rosen.